ConductScience.org, home

Paper41999190

A Clinical-Radiomics Nomogram Predicts Early Tumor Necrosis After Transarterial Chemoembolization for Hepatocellular Carcinoma.

Wu XL and 5 others. Technol Cancer Res Treat, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. A Clinical-Radiomics Nomogram Predicts Early Tumor Necrosis After Transarterial Chemoembolization for Hepatocellular Carcinoma. Papers, record 41999190. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41999190

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Clinical-Radiomics Nomogram Predicts Early Tumor Necrosis After Transarterial Chemoembolization for Hepatocellular Carcinoma.
PubMed
Journal
Technol Cancer Res Treat
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wu XLXiang-Linghttps://orcid.org/0009-0004-1890-6326
2Duan BZBing-Zhi
3Jiang ZHZhi-Hua
4Zeng SSShan-Shan
5Lin GCGuo-Cheng
6Fang ZLZhong-Liao

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Liver NeoplasmsMajor topic
Carcinoma, HepatocellularMajor topic
Chemoembolization, TherapeuticMajor topic
NomogramsMajor topic
Humans
Radiomics
Female
Necrosis
Male
Middle Aged
Aged
Treatment Outcome
Prognosis
ROC Curve
Tomography, X-Ray Computed

Source PubMed

Download CSV of topics

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129662837Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.Liver Cancer2018https://conductscience.org/library/papers/29662837PubMed
2267629423D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.Eur Radiol2016https://conductscience.org/library/papers/26762942PubMed
331698504Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.Hepatology2020https://conductscience.org/library/papers/31698504PubMed
417938396The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.Ann Intern Med2007https://conductscience.org/library/papers/17938396PubMed
538448905Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score.BMC Cancer2024https://conductscience.org/library/papers/38448905PubMed
640075740Integrating CT Radiomics and Clinical Features to Optimize TACE Technique Decision-Making in Hepatocellular Carcinoma.Cancers (Basel)2025https://conductscience.org/library/papers/40075740PubMed
732060219Introduction to Radiomics.J Nucl Med2020https://conductscience.org/library/papers/32060219PubMed
836631548CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients.Sci Rep2023https://conductscience.org/library/papers/36631548PubMed
935070032Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?World J Gastrointest Oncol2021https://conductscience.org/library/papers/35070032PubMed
1034765303Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma.Am J Cancer Res2021https://conductscience.org/library/papers/34765303PubMed
1139747344Application of the Lasso regularisation technique in mitigating overfitting in air quality prediction models.Sci Rep2025https://conductscience.org/library/papers/39747344PubMed
1235941241Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis.Cardiovasc Intervent Radiol2022https://conductscience.org/library/papers/35941241PubMed
1321703196EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.J Hepatol2011https://conductscience.org/library/papers/21703196PubMed
1438606106A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.Front Oncol2024https://conductscience.org/library/papers/38606106PubMed
1537519801Radiomics features of computed tomography and magnetic resonance imaging for predicting response to transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis.Front Oncol2023https://conductscience.org/library/papers/37519801PubMed
1634729109Predicting early refractoriness of transarterial chemoembolization in patients with hepatocellular carcinoma using a random forest algorithm: A pilot study.J Cancer2021https://conductscience.org/library/papers/34729109PubMed
1734907081Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies.Clin Cancer Res2022https://conductscience.org/library/papers/34907081PubMed
1830360019Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization.Korean J Intern Med2019https://conductscience.org/library/papers/30360019PubMed
1923884657The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository.J Digit Imaging2013https://conductscience.org/library/papers/23884657PubMed
2030129899Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization?Radiology2018https://conductscience.org/library/papers/30129899PubMed

See all 39 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41999190

GET https://conductscience.org/api/papers/v1/41999190/references?page=2